Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis

作者：David F. McDermott, Brian I. Rini, Robert J. Motzer, Nizar M. Tannir, Bernard Escudier, Christian Kollmannsberger, Hans J. Hammers, Camillo Porta, Saby George, Frede Donskov, Howard Gurney, Marc‐Oliver Grimm, Michael R. Harrison, Thomas E. Hutson, J. Doan, Shuo Yang, S. Rao, Sabeen Mekan, Apoorva Ambavane, Thomas Powles · 发表于：Annals of Oncology · 年份：2018 · DOI：10.1093/annonc/mdy283.083 · 被引用次数：19 · 研究领域：Cancer Immunotherapy and Biomarkers、CAR-T cell therapy research、Renal cell carcinoma treatment

Background: Pts with metastatic melanoma who discontinue N+I may experience sustained clinical benefit and a delayed need for subsequent therapy. In this analysis, TFI was retrospectively analyzed using data from the phase 3 CheckMate 214 trial, in which N+I demonstrated superior efficacy vs S in pts with IMDC intermediate/poor (int/poor)-risk aRCC.